Background: Cerebral vasospasm (CVS) is well known as a major complication in subarachnoid hemorrhage (SAH) patients, and research has long been focused on improving morbidity and mortality. As CVS commonly develops from day 4 to day 14 after SAH onset, SAH patients require therapies with drugs for preventing CVS after surgical treatment for the source of hemorrhage, mostly ruptured intracranial aneurysms. It is thought that the pathogenesis of CVS is initiated by prolonged smooth muscle contraction, and the subsequent hypoperfusion and cytotoxic responses induce cerebral ischemia. Although therapeutic investigations have historically focused on morphological improvement, the improvement of outcome is limited by the reversal of arterial narrowing. Therefore, it might be important to look back at evidence from long-lasting studies of CVS and to determine a highroad to effective drugs, including combination therapy.Objective: In this review, we introduce current candidate beneficial drugs against CVS in clinical SAH, including nimodipine and other Ca2+ channel antagonists, magnesium sulfate, clazosentan, statins, cilostazol, eicosapentaenoic acid, fasudil hydrochloride, milrinone, and edaravone, all of which have been frequently studied in recent years.
Keywords: Arterial narrowing, cerebral vasospasm, drugs, early brain injury, pathophysiology, subarachnoid hemorrhage.
Current Theories and Clinical Trial Evidence for Limiting Human Abdominal Aortic Aneurysm Growth
Current Drug Targets Effects of Acute and Chronic Biomechanical Strain on Human Cerebral Endothelial Cells in Altering their Proteome Profile
Current Proteomics Endovascular Versus Open Abdominal Aortic Aneurysm: Best Decision
Current Pharmaceutical Design Chymase Inhibitor As a Novel Therapeutic Strategy for Anti-Vascular Remodeling
Vascular Disease Prevention Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Contributory Role of Matrix Metalloproteinases in Cardiovascular Remodeling
Current Drug Targets - Cardiovascular & Hematological Disorders Patient-Specific Modeling and Multi-Scale Blood Simulation for Computational Hemodynamic Study on the Human Cerebrovascular System
Current Pharmaceutical Biotechnology Dissecting abdominal aortic aneurysm in Angiotensin II-infused mice: the importance of imaging
Current Pharmaceutical Design Angiotensin II and Abdominal Aortic Aneurysms: An update
Current Pharmaceutical Design Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk
Current Pharmaceutical Design Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature
Current Drug Targets Ulnar Artery Thrombosis Due to Hypothenar Hammer Syndrome
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Spectrophotometric Quantification of Bilirubin in Hemorrhagic Spinal Fluid using an Innovative Algorithm
Medicinal Chemistry The Role of Oxidative Stress in Cerebral Aneurysm Formation and Rupture
Current Neurovascular Research Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Different Factors Influence Recanalisation Rate After Coiling in Ruptured and Unruptured Intracranial Aneurysms
CNS & Neurological Disorders - Drug Targets Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Circadian Variation of Cardiovascular Events and Morning Blood Pressure Surge
Vascular Disease Prevention Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Endothelial Progenitor Cells (EPCs) Evaluation in Aortic Aneurysm Repair
Current Vascular Pharmacology